DOC1021

BIOLOGICAL2 trials

Sponsors

Diakonos Oncology Corporation

Conditions

Glioblastoma (GBM)Refractory Melanoma

Phase 1

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

RecruitingNCT07288112

Diakonos Oncology CorporationRefractory Melanoma

Start: 2026-02-23End: 2033-01-01Target: 35Updated: 2026-02-23

Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

RecruitingNCT06805305

Diakonos Oncology CorporationGlioblastoma (GBM)

Start: 2025-03-17End: 2032-03-01Target: 180Updated: 2026-03-24

Related Papers

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma

medRxiv2026-04-02